Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension

Trial Profile

A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ralinepag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2019 Primary endpoint (Change from baseline in 6-min walk distance (6MWD) in patients with PAH) has not been met as per results published in the European Respiratory Journal
    • 07 Aug 2019 Results published in the European Respiratory Journal
    • 06 Apr 2019 Results of post-hoc analysis assessing a significant correlation of ralinepag plasma levels in patients with pulmonary arterial hypertension, presented at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top